OverviewSuggest Edit

Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products. It offers endocrinology products for the treatment of diabetes, osteoporosis in postmenopausal women and men, and human growth hormone deficiency and pediatric growth conditions. The Company also provides neuroscience products for the treatment of the depressive disorder, diabetic peripheral neuropathic pain, anxiety disorder, fibromyalgia, and chronic musculoskeletal pain, schizophrenia, attention-deficit hyperactivity disorder, obsessive-compulsive disorder, bulimia nervosa, panic disorder, and more.

TypePublic
Founded1876
HQIndianapolis, US
Websitelilly.com
Employee Ratings3.6
Culture scoreB

Latest Updates

Employees (est.) (Dec 2019)33,625(-13%)
Job Openings425
Revenue (FY, 2019)$22.3 B(-9%)
Share Price (May 2020)$159.2

Key People/Management at Eli Lilly

David A. Ricks

David A. Ricks

Chairman and Chief Executive Officer
Melissa Stapleton Barnes

Melissa Stapleton Barnes

Senior Vice President, Enterprise Risk Management, and Chief Ethics and Compliance Officer
Enrique A. Conterno

Enrique A. Conterno

Senior Vice President and President, Lilly Diabetes and Lilly USA
Stephen F. Fry

Stephen F. Fry

Senior Vice President, Human Resources and Diversity
Michael J. Harrington

Michael J. Harrington

Senior Vice President and General Counsel
Johna L. Norton

Johna L. Norton

Senior Vice President, Global Quality
Show more

Eli Lilly Office Locations

Eli Lilly has offices in Indianapolis, Amarillo, Arlington Heights, Bakersfield and in 141 other locations
Indianapolis, US (HQ)
893 Delaware St
Melrose Park, AU
112 Wharf Rd
Wien, AT
8-10 Kölblgasse
Toronto, CA
3650 Danforth Ave
Chuo Ward, JP
Sannomiya Plaza Building 7-1-5 Isogami-dori Chuo-ku, Kobe
Windlesham, GB
Erl Wood Manor Sunninghill Road
Show all (196)

Eli Lilly Financials and Metrics

Eli Lilly Revenue

Embed Graph
View revenue for all periods
Eli Lilly's revenue was reported to be $22.32 b in FY, 2019
USD

Revenue (Q1, 2020)

5.9b

Gross profit (Q1, 2020)

4.6b

Gross profit margin (Q1, 2020), %

79.3%

Net income (Q1, 2020)

1.5b

Market capitalization (15-May-2020)

152.3b

Closing stock price (15-May-2020)

159.2
Eli Lilly's current market capitalization is $152.3 b.
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Revenue

23.1b19.6b20.0b21.2b22.9b24.6b22.3b

Revenue growth, %

(15%)2%6%

Cost of goods sold

4.9b4.9b5.0b5.7b6.1b6.4b4.7b

Gross profit

18.2b14.7b14.9b15.6b16.8b18.1b17.6b
Quarterly
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Cash

3.8b3.9b3.7b4.6b6.5b8.0b2.3b

Accounts Receivable

588.4m566.7m558.6m736.9m4.5b5.2b4.5b

Prepaid Expenses

1.4b2.1b2.5b

Inventories

2.9b2.7b3.4b3.6b4.5b4.1b3.2b
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Net Income

4.7b2.4b2.4b2.7b(204.1m)3.2b8.3b

Depreciation and Amortization

1.6b1.6b1.2b

Inventories

(253.9m)7.8m(258.7m)

Accounts Payable

916.3m(284.5m)(477.7m)
Quarterly
USDQ1, 2010Q2, 2010Q3, 2010Q4, 2010Q1, 2011Q2, 2011Q3, 2011Q4, 2011Q1, 2012Q2, 2012Q3, 2012Q4, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020

Net Income

1.2b1.3b1.3b5.1b1.1b1.2b1.2b4.3b1.0b1.9b3.3b4.1b1.5b2.8b4.0b727.9m1.5b2.0b529.5m1.1b1.9b440.1m1.2b2.0b(110.8m)897.2m1.5b1.2b957.5m2.1b4.2b5.6b6.8b1.5b

Depreciation and Amortization

(299.4m)1.3b340.9m1.4b385.9m747.9m1.1b1.5b381.5m745.4m1.1b348.8m697.2m1.0b357.5m726.0m1.1b385.5m759.2m1.2b386.9m782.5m1.2b422.8m848.0m1.3b356.5m603.9m891.9m273.6m

Inventories

(157.0m)203.1m(307.9m)

Accounts Payable

(363.9m)591.4m(336.1m)
USDY, 2020

Financial Leverage

12.9 x
Show all financial metrics

Eli Lilly Operating Metrics

FY, 2013FY, 2014FY, 2015FY, 2016

Phase III Trials Products

8 7 17 19

Projects in R&D Pipeline

57 57 65 66
Show all operating metrics

Eli Lilly Acquisitions / Subsidiaries

Company NameDateDeal Size
DermiraJanuary 10, 2020$1.10 b
Loxo OncologyJanuary 07, 2019$8 b
AurKa PharmaMay 15, 2018$575 m
ARMO BioSciences IncMay 11, 2018$1.60 b
CoLucid PharmaceuticalsJanuary 18, 2017$960 m
Novartis Animal HealthApril 22, 2014$5.40 b
Avid RadiopharmaceuticalsNovember 08, 2010$800 m
Alnara PharmaceuticalsJuly 02, 2010$280 m
Imclone SystemsOctober 06, 2008$6.50 b

Eli Lilly Online and Social Media Presence

Embed Graph

Eli Lilly Company Culture

  • Overall Culture

    B

    70/100

  • CEO Rating

    A

    76/100

  • Compensation

    A

    78/100

  • Diversity

    C+

    65/100

Learn more on Comparably

Eli Lilly News and Updates

Drugmaker Eli Lilly starts clinical testing of therapies for COVID-19

U.S. Drugmaker Eli Lilly & Co said on Friday it began clinical testing of therapies for the COVID-19 illness caused by the coronavirus.

Eli Lilly to study use of arthritis drug to treat COVID-19

Eli Lilly and Co. said late Friday it has reached an agreement with the National Institutes of Health to study one of its drugs as a COVID-19 treatment. Baricitinib, marketed as Olumiant, is approved in more than 65 countries as a treatment for adults with moderately to severely active rheumatoid a…

Eli Lilly lowers insulin costs as coronavirus crisis deepens

Drugmaker Eli Lilly said on Tuesday it has capped the out-of-pocket cost for insulin to $35 per month to help diabetes patients across the United States, many of whom are facing financial difficulties due to the coronavirus outbreak.

Eli Lilly offers new $35 co-pay insulin value program during coronavirus pandemic

Eli Lilly & Co. said Tuesday it is introducing a Lilly Insulin Value Pogram, allowing anyone with insurance and those without insurance to fill their monthly insulin prescription for $35. The program has been launched with immediate effect and covers most Lilly insulins, the company said in a s…

UPDATE 3-U.S. court rules for Teva in migraine patent dispute with Eli Lilly

Teva Pharmaceutical Industries Ltd on Tuesday won a ruling from a U.S. administrative court that could help it fend off competition from Eli Lilly and Co in the market for migraine drugs.

Thinking about trading options or stock in Akamai Technologies, Citrix Systems, Eli Lilly, Veeva Systems, or Walmart?

NEW YORK, March 19, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AKAM, CTXS, LLY, VEEV, and WMT. Click a link below then choose between in-depth options trade idea report or a stock score report. Options Report – Ideal trade ideas on up to seven different...
Show more

Eli Lilly Frequently Asked Questions

  • When was Eli Lilly founded?

    Eli Lilly was founded in 1876.

  • Who are Eli Lilly key executives?

    Eli Lilly's key executives are David A. Ricks, Melissa Stapleton Barnes and Enrique A. Conterno.

  • How many employees does Eli Lilly have?

    Eli Lilly has 33,625 employees.

  • What is Eli Lilly revenue?

    Latest Eli Lilly annual revenue is $22.3 b.

  • What is Eli Lilly revenue per employee?

    Latest Eli Lilly revenue per employee is $663.8 k.

  • Who are Eli Lilly competitors?

    Competitors of Eli Lilly include Becton Dickinson, Bristol-Myers Squibb and MannKind Corporation.

  • Where is Eli Lilly headquarters?

    Eli Lilly headquarters is located at 893 Delaware St, Indianapolis.

  • Where are Eli Lilly offices?

    Eli Lilly has offices in Indianapolis, Amarillo, Arlington Heights, Bakersfield and in 141 other locations.

  • How many offices does Eli Lilly have?

    Eli Lilly has 196 offices.